ValueStockFinder

Highlights

Every trading day, ValueStockFinder scans around 3,500 companies to identify where growth momentum is accelerating most. We analyse how revenue and EPS growth develop over multiple quarters and combine this with changing analyst expectations to identify companies gaining momentum.

September 11, 2026: Apollo EPS Swings from -11% to +64% on Record Earnings

Apollo Global Management’s current EPS growth surged to 64.49%, a dramatic reversal from the prior -11.07% average, driven by record fee-related and spread-related earnings. This 75.55-percentage-point improvement reflects the recovery in insurance margins and volume-led growth across its integrated credit and retirement platform.

Simultaneously, revenue growth turned sharply positive to 38.14% from -15.04%, confirming broad-based strength beyond volatile equity realizations. The full fundamental analysis in the portal details how the trillion-dollar AUM base and Athene’s stable funding are reinforcing the structural earnings power.

September 9, 2026: Chord Energy: EPS growth swing of +296 percentage points

Chord Energy’s current EPS growth surged from -35.84% to 259.78% compared with the prior four-quarter average, an absolute improvement of 295.62 percentage points. Simultaneously, revenue growth jumped from 0.39% to 84.04%, an 83.64-percentage-point gain that reflects higher oil production above guidance and operational outperformance in the Williston Basin.

As the largest Williston acreage holder, Chord translates its long‑lateral drilling and cost advantages into sharply higher cash generation when commodity realizations are favorable. The current analysis shows trailing EPS of $14.80, an operating margin of 34.72%, and a strong balance sheet—yet consensus forward estimates still anticipate a meaningful contraction next year. This contrast makes the company’s latest fundamental momentum worth a closer independent look in the full analysis.

September 3, 2026: Corcept: Forward EPS Growth Surges Past 100%

Corcept Therapeutics saw its forward EPS growth climb from 87.28% to 104.77% within a 30-day window, an absolute increase of 17.49 percentage points. Forward revenue growth similarly strengthened from 41.05% to 48.75%, while reported quarterly revenue growth accelerated sharply from an average of 12.12% to 31.74%. These improvements reflect a Q2 earnings beat, raised full-year 2026 guidance, and the resubmission of the relacorilant NDA, strengthening the investment thesis as the company transitions from a single-product Cushing’s franchise toward a multi-product cortisol-modulation platform.

For private investors focused on long-term quality, this shift in consensus forward estimates signals that the anticipated recovery is materializing faster than expected, supported by an established endocrinology base and a debt-free balance sheet with over half a billion dollars in cash. The update underscores how the combination of commercial execution and regulatory progress can alter the growth and earnings outlook of a specialty biopharmaceutical company. The full analysis in the portal explores the durability of this trajectory and the remaining execution risks.

September 2, 2026: Perseus Mining: Forward EPS Growth Jumps from 21% to 54%

Forward EPS growth for Perseus Mining surged from 21.06% to 54.29% (+33.23 pp) in the 30-day window, while forward revenue growth rose to 36.43% (+10.27 pp). This sharp upward revision reflects strengthening earnings expectations for the West African gold producer, supported by a net-cash balance sheet and progress at the Nyanzaga project.

Additionally, current revenue growth turned from -9.84% to +21.45%, confirming a cyclical recovery. These signals highlight a potential re-rating of the investment thesis. Read the full analysis for a deeper look at the quality, growth, and valuation drivers.

September 1, 2026: Prudential plc Revenue Growth Jumps to 191.85%, EPS Up 39.7%

Prudential plc’s current revenue growth surged to 191.85% and forward EPS growth rose to 17.09%. The jump reflects strong insurance and asset management income across Asia and Africa, driven by a shift to higher-margin health and protection products.

The full analysis details how mix-led margin expansion and capital returns support the case, with Greater China regulatory risk as a key watchpoint.

August 31, 2026: Strathcona Resources: Forward Growth Estimates Surge After Record Q2

Strathcona Resources’ forward EPS growth jumped from 8.85% to 15.78% and revenue growth from 10.43% to 23.33% in the latest window. This follows record Q2 free cash flow of C$296 million, confirming its long-life oil sands assets.

The upward revision reflects higher oil prices and cost discipline. The full analysis examines whether this cyclical upswing can support a durable thesis for this heavy oil producer.

August 26, 2026: Onto Innovation: Revenue Growth Surges from 0.44% to 35.30% on AI Tailwinds

Revenue growth surged from 0.44% to 35.30% (rank 96.7/100) and EPS growth swung from -14.79% to +54.40% (rank 89/100), driven by record demand for advanced packaging and AI-related process control tools.

Forward EPS growth rose from 38.22% to 43.83% and forward revenue growth from 21.66% to 29.97% over 30 days, reflecting analyst upgrades after a strong Q2 beat. The full analysis assesses whether the premium valuation already captures this momentum.

August 25, 2026: Trekor Metals: Revenue Growth Surges 574% as Florence Copper Ramps Up

Current revenue growth surged from 27.42% to 184.76%, a relative jump of 573.92%, as the Florence Copper in-situ recovery operation in Arizona reached commercial production and added a second low-cost output engine alongside the Gibraltar mine.

Forward EPS growth also improved markedly from 77.44% to 94.35%, reflecting analysts’ rising earnings estimates. The full analysis in the portal examines the investment thesis, valuation, and risks around this North American copper producer’s structural growth story.

August 24, 2026: Geely Automobile: Current Revenue Growth Rises to 136.16%

Geely Automobile’s current revenue growth rose from 41.58% to 136.16% versus the prior four-quarter average (+94.58 pp; +227.45%). Forward revenue growth rose from 15.20% to 19.54%, and forward EPS growth from 19.31% to 22.57%.

This indicates stronger growth expectations. Geely makes passenger vehicles under Geely, Lynk & Co and Zeekr, including new energy and electrified models; the analysis highlights expansion through premium mix and exports. Read the full analysis for further research.

August 21, 2026: Mandatum: EPS Growth Reverses to +117%, Revenue to +1,138%

Mandatum’s EPS growth swung from -31.43% to 116.67% (+148.10 pp) and revenue growth from -34.49% to 1,138.37% (+1,172.86 pp) vs. the prior four-quarter average. This reflects record AuM of EUR 16.7bn and a shift to capital-light fee income.

Its Finnish corporate pension franchise and Nordic expansion support the improved growth quality. The full analysis examines sustainability and valuation.

August 20, 2026: International Seaways: EPS Growth Surges from 3.98% to 387.50%

International Seaways’ trailing EPS growth vs. the prior four-quarter average surged from 3.98% to 387.50% (a 383.52 pp increase). Revenue growth turned from -8.08% to 77.47%, an 85.55 pp swing.

The surge reflects exceptional tanker rate strength and fleet optimization across crude and product carriers. The full analysis examines how the market’s cyclical discount and the company’s fortress balance sheet shape the investment case.

August 19, 2026: Indivior's Revenue Growth Jumps: Current Revenue Surges from 4.17% to 19.17%

Indivior's current revenue growth surged from 4.17% to 19.17%, a sharp acceleration driven by its leading long-acting injectable SUBLOCADE. This improvement, alongside upticks in forward EPS growth (8.13% to 10.77%) and forward revenue growth (4.15% to 5.07%), underscores strengthening operational momentum in the opioid use disorder treatment market.

The full analysis in the portal examines how these growth signals, combined with a structurally reset cost base and an accretive merger, reshape the investment thesis.

Notice: ValueStockFinder does not provide investment advice and does not issue recommendations to buy, hold or sell securities or other financial instruments. We are neither a provider nor an intermediary of financial products and do not name, recommend or arrange such providers.

We analyse listed companies exclusively from a fundamental perspective. The analyses are created automatically with the support of artificial intelligence; the underlying data comes from external sources, for whose accuracy and completeness no guarantee is given.

The content is provided for your own independent decision-making and does not take into account the personal financial situation, investment objectives, knowledge, experience or risk tolerance of users. Every investment decision is made at your own responsibility. Investments involve risks and may result in losses.

Stock Advisor

Ticker: CME
Region: America
Sub-region: North America
Country: United States

ISIN: US12572Q1058
Industry: Financial Data & Stock Exchanges

Fundamental analysis as of 24.07.2026

Next analysis on: 23.10.2026

Score

(–) Strong

CME combines dominant derivatives market share with exceptional operating leverage, driving strong growth and high margins. However, current peak cyclical volumes and an elevated valuation limit upside, making it a high-quality hold rather than a compelling buy.

CME Group is a high-quality compounder with a durable moat, currently priced for steady mid-single-digit growth rather than the exceptional cyclical peak it is experiencing. The core investment case rests on structural volume growth and pricing power, not on sustained record volatility.

The decisive strengths are its liquidity-driven network effects in U.S. interest rate and equity index futures, a vertically integrated CCP that locks in trading flow, and a recurring market data business with over 30 consecutive quarters of growth. This combination produces industry-leading operating margins and strong cash generation. The most critical trade-off is that current record volumes and profitability are cyclical peaks; as macro volatility normalizes, growth will likely revert to mid-single digits, making the forward P/E of 19.8x and PEG of 3.6x demanding. Financial stability is robust, but aggressive capital returns have marginally increased leverage.

Overall quality is high, justified by structural competitive advantages and a scalable model. However, the current valuation offers a limited margin of safety for a cyclical normalization. The investment is suitable for long-term, quality-focused investors who can look through a potential earnings dip, but less so for those seeking near-term capital appreciation from multiple expansion.

**Conclusion: The investment is to be assessed as "worth watching".** The company is a premier asset, but the current price already reflects peak-cycle earnings and a premium for quality, leaving little room for error if volumes moderate.

The investment story has improved: CME's Q1 2026 results confirm record volumes and margins, reinforcing the quality-growth thesis despite elevated cyclical risks. The most decisive change is the confirmation of broad-based double-digit growth in Q1 2026, compared to the previous analysis which only showed 8.1% revenue growth in Q4 2025. Then, growth was driven by clearing fees and market data; now, it is explicitly volume-dominated with record average daily volume across all asset classes and regions, translating into record clearing and transaction fee revenue. This shift from moderate to exceptional growth is structural in its diversification—international activity growing faster than the group average—but cyclical in its magnitude, as management kept expense guidance flat, implying they view current conditions as robust but not permanent. Profitability has also improved: the operating margin rose from 64.4% in the prior analysis to 69.8% now, with management reporting that a large majority of revenue growth converted into higher adjusted net income, underscoring significant operating leverage. This margin expansion is partly structural due to the scalable technology platform, but the current level embeds unusually elevated volumes and favorable rate-driven income, suggesting it may be past peak levels. Financial stability has marginally weakened due to aggressive capital returns, with net debt/EBITDA rising from 0.18x to 0.24x, but interest coverage remains very high at 29.7x, so the risk is limited. The original investment thesis—that CME is a high-quality, capital-light exchange with durable competitive advantages—has been confirmed and strengthened by the latest results. The moat remains anchored in liquidity-driven network effects and regulatory barriers, with record volumes across all asset classes suggesting the moat is still gradually strengthening. The risk-reward profile has shifted: while the valuation premium remains justified by scarcity and quality, the cyclical peak in volumes introduces greater mean-reversion risk. The current analysis explicitly warns that current profitability is above long-term averages and that investors should expect normalization if macro uncertainty declines. This does not change the investment assessment for a long-term holder focused on compounding, but it reduces the margin of safety for new entries. The thesis is intact, but the cyclical timing is less favorable than in the prior analysis, where the setup was still early in the recovery phase.

Score

(2.7)

Metric	Value	Peer median
P/E	23.3	18.7
Forward P/E	21.3	16.7
PEG	4.22	1.42

Company Peer median

CME Group’s current valuation embeds a clear quality and scarcity premium rather than a classic value profile. The market is paying up for a business that combines structurally high operating margins, strong cash generation, and dominant competitive positioning in derivatives trading and market data, as evidenced by record Q2 revenue, earnings, and non-transaction data income. Forward multiples implicitly assume that CME can sustain mid-single-digit or better revenue growth and protect its profitability despite a normalized volatility backdrop after exceptionally strong prior years. Given flat reported revenue year over year in Q2 but continued beats versus consensus and record first-half results, expectations look demanding but not extreme for a high-quality, capital-light exchange model. The valuation will be sensitive to evidence that current volume and open-interest strength is durable through a less supportive macro or rate cycle, and to management’s ability to keep expanding non-transactional revenue streams like market data, which have delivered multi-year, consecutive quarterly growth. Any slowdown in earnings growth, pressure on rate-related collateral income, or regulatory changes affecting derivatives activity could trigger a de-rating, while sustained beats on earnings and increased capital returns via buybacks and special dividends would support an upward re-rating. At present there is no obvious disconnect between price and fundamentals; the stock appears priced for continued high-quality compounding rather than for step-change acceleration.

Score

(1.8)

Metric	Value	Peer median
Revenue growth YoY	0.8%	15.3%
Revenue growth +1Y	4.7%	8.3%
EPS growth YoY	1.0%	24.6%
EPS growth +1Y	5.5%	13.2%
Free cash flow growth	2.6%	-8.6%

Revenue

CME delivered broad-based double-digit revenue and EPS growth in Q1 2026, driven primarily by record trading volumes and resilient pricing. Management highlighted average daily volume at an all-time high across all asset classes and regions, translating into record clearing and transaction fee revenue and continued double-digit growth in market data fees. Volume growth was supported by elevated rates and macro volatility, with international activity growing faster than the group average, which structurally diversifies the franchise. Growth neither accelerated nor decelerated meaningfully versus the prior quarter, but the mix was clearly volume-dominated. The structural elements are CME’s global distribution, product breadth and recurring data revenues, evidenced by more than 30 consecutive quarters of market data growth. Cyclical tailwinds include heightened uncertainty in rates, FX and commodities that may normalize. Key risks are a potential decline in volatility, regulatory changes impacting derivatives usage, and competition for liquidity. Consensus expects clearly lower growth over the next year, implying that current momentum is unlikely to be repeated absent another spike in macro stress. Over 12 to 24 months, moderate mid-single-digit revenue and EPS growth appears more realistic, anchored in steady volumes, incremental product innovation and pricing discipline rather than another step-change in activity.

Score

(8.5)

Metric	Value	Peer median
ROCE	14.2%	10.9%
ROIC	14.0%	10.8%
EBIT margin	65.0%	39.1%
Trailing EPS	11.8500	3.7650

ROCE

Profitability in Q1 2026 was exceptionally strong, with operating margins at historic highs as incremental revenue flowed disproportionately to the bottom line. Management reported that a large majority of the year-on-year revenue increase converted into higher adjusted net income, underscoring significant operating leverage in the futures and options model. The key drivers were strong clearing and transaction fee growth, higher market data revenue, and disciplined expense control, with only modest cost inflation relative to revenue. This combination boosted EBIT margins and supported high double-digit earnings growth. Structurally, CME benefits from a scalable technology platform and network effects that allow volumes to grow far faster than fixed costs, supporting sustainably high returns on capital. The slight quarter-on-quarter decline in ROCE and ROIC likely reflects timing of capital returns and balance sheet movements rather than a deterioration in the core franchise. Over the next 12 to 24 months, profitability is likely to remain very strong but may be past peak levels, as current margins embed unusually elevated volumes and favorable rate-driven income streams. Headwinds could arise from normalization of trading activity, higher regulatory or technology spend, and competitive pricing pressure, though management’s cost discipline and focus on high-value data and services still leave room for incremental efficiency gains rather than structural margin compression.

Score

(9.5)

Metric	Value	Peer median
Net debt/EBITDA	0.2	0.2
Net debt / FCF	0.3	0.3
Debt / Capital	11.4%	39.4%
Interest coverage	29.7	8.6

Net debt / EBITDA

CME Group’s balance sheet appears conservatively financed, with moderate leverage and ample cash relative to debt, supported by strong, recurring cash flows from clearing and market data revenues. The slight increase in leverage ratios quarter on quarter suggests incremental debt or reduced cash following sizable capital returns through dividends and buybacks, rather than operational stress. Interest coverage remains very high thanks to robust operating income and sizeable earnings from performance bond and guaranty fund contributions, indicating that the company can comfortably meet interest and principal payments even if rates rise or volumes moderate. There is limited refinancing risk in the near term given the company’s scale, investment-grade profile, and access to capital markets, and no signs of liquidity strain as cash balances remain substantial after shareholder distributions. Structurally, CME’s fee-based model, variable cost base, and minimal capex requirements provide resilience to economic downturns, although a sharp, prolonged drop in trading activity or regulatory shocks could compress earnings and reduce cushion over time. Overall, financial stability has marginally weakened due to aggressive capital returns, but remains strong, with the capital structure and liquidity profile well aligned with the relatively low-cyclical nature of its core businesses.